Cite
HARVARD Citation
McInnes, I. et al. (n.d.). SAT0189 Rapid Onset of Clinical Benefit in Patients with RA Treated with Mavrilimumab, A Fully Human Monoclonal Antibody Targeting GM–CSFR-ALPHA: Subanalysis of the Phase IIB Earth Explorer 1 Study. Annals of the rheumatic diseases. pp. 723-724. [Online].